Recognizing and referring patients with possible inherited cancer predisposition syndromes for appropriate genetic evaluation and testing provides insights into optimal patient treatment approaches and also can provide education and testing opportunities for family members. Next-generation sequencing (NGS)-based, targeted genotyping for somatic mutations is increasingly used in the diagnosis, prognostication, and treatment selection for patients with hematologic malignancies. However, certain mutations that may be somatically acquired can also be present as germline mutations in some individuals and families. Whether the results of NGSbased leukemia panels can be used to inform decisions and subsequent evaluation of patients with possible inherited cancer predispositions has not been described previously. Because a normal control often is not available when using NGS panels in patients with hematologic malignancies, NGS panel results offer both an opportunity and a challenge to determine the origin and pathogenicity of identified mutations. In the absence of a matched germline control, variant allele frequency (VAF) estimation and data from publically available data sets provide important clues to the possible germline origin of a variant. Careful annotation and review of NGS panels in patients with hematologic malignancies can provide a useful screening tool to systematically improve upon the detection of potentially pathogenic germline variants. Cancer 2018;124:2704-13.
INTRODUCTION
Inherited cancer predisposition syndromes, such as hereditary breast and ovarian cancer caused by germline breast cancer BRCA and BRCA2 mutations or hereditary nonpolyposis colorectal cancer (HPNCC) related to germline mutations in the mismatch-repair genes (ie, MLH1, MSH2, MSH6, and PMS2), are well described and clinically recognized and occur in approximately 3% to 10% of all cancers. [1] [2] [3] [4] Hereditary predispositions to hematologic malignancies, however, have long been considered rare, particularly among adult patients. Despite the recognition of families with clustering of hematologic malignancies since the early 1900s, it is only in the past decade that multiple genes have been associated with an inherited risk of hematologic cancers. 5, 6 An overview of the clinically recognized inherited predisposition syndromes associated with hematologic malignancies is provided in Table 1 .
Next-generation sequencing (NGS)-based, targeted genotyping for somatic mutations is increasingly used in patients with hematologic malignancies to improve diagnosis, prognostication, and treatment selection. As NGS infrastructure and technology continues to advance, cancer-specific NGS panels are quickly becoming a more cost-effective and timely approach in routine clinical care to analyze for the presence of multiple prognostic and/or targetable genomic alterations at once. At the same time, the increasing use of NGS-based evaluations has demonstrated that mutations that were previously considered to be somatically acquired can also be present as germline mutations in certain families. Indeed, several of the familial myelodysplastic syndrome/acute myeloid leukemia (MDS/AML)-predisposition syndromes are now recognized in the 2016 update to the World Health Organization myeloid classification system. 7 However, given the complexity of obtaining a germline normal control in patients with active hematologic malignancies, much of the 
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Cancer currently performed genetic testing does not include a germline sample; therefore, a determination of whether identified mutations are inherited or acquired is not overtly possible. Whether results from NGS-based leukemia panels could be used to inform decisions and subsequent evaluation of patients with possible inherited cancer predispositions has not been previously described. Recognizing and referring patients with possible inherited cancer predispositions for evaluation, genetic testing, and management not only provide insight into optimal treatment strategies for the patient but also can provide education, testing, and support for family members. In recent reviews, we and others have demonstrated that, among patients with hematologic malignancies who are referred for clinical genetic testing, germline predispositions can be identified in 12% to 19%, which overlaps with the rate of detection of hereditary cancer syndromes among patients with solid tumors and reinforces the position that inherited hematologic malignancies are not as rare as previously thought. 8, 9 Increased provider awareness and improved methods to clinically and pathologically identify patients who are at risk for an inherited predisposition are paramount.
CLINICAL EVALUATION TO IMPROVE GERMLINE DETECTION
A family history of hematologic malignancies, such as 1 first-degree relative or 2 second-degree relatives, should raise the consideration that a patient has an underlying genetic predisposition. In addition, patients and families with inherited mutations that lead to hereditary hematologic malignancies frequently have identifying characteristics or laboratory abnormalities, although clinical features may be subtle or even absent in many of the inherited predisposition syndromes. 10, 11 This finding is highlighted by the recent increased identification of patients with inherited bone marrow failure syndromes, such as Fanconi anemia (FA), dyskeratosis congenita, and Diamond-Blackfan anemia in adulthood. [12] [13] [14] Well described and characteristic clinical features, including short stature, congenital malformations, or dysmorphology, are reported with each syndrome in the pediatric literature, as detailed in Table  1 ; however, 10% or more patients with FA and most patients with dyskeratosis congenita are diagnosed as adolescents or young adults, who often lack the characteristic stigmata. Other disorders, such as GATA binding protein 2 (GATA2) syndrome, also known as MonoMac or Emberger syndrome, or MIRAGE (myelodysplasia, infection, growth restriction, adrenal hypoplasia, genital phenotypes, and enteropathy) syndrome related to sterile a motif domain containing 9 (SAMD9) mutations, are more frequently associated with immunodeficiency and frequent atypical infections, which may raise suspicion for an inherited predisposition. 15, 16 Other MDS and acute leukemia predisposition syndromes, such as runt-related transcription factor 1 (RUNX1), ankyrin repeat domain 26 (ANKRD26), and ETS variant 6 (ETV6), are primarily associated with a history of 1 or more cytopenias (often mild-to-moderate thrombocytopenia with abnormal platelet function). [17] [18] [19] [20] Still other inherited leukemia predispositions, including CCAAT/enhancer-binding protein a (CEBPA) and DEAD-box helicase 41 (DDX41), are currently lacking any known associated clinical or laboratory features to assist in their identification before the development of overt malignancy. [21] [22] [23] Suspicion for germline inheritance also may be elicited in the situation of certain biallelic mutations, for example, CEBPA mutations, in which approximately 10% of patients with biallelic, or dual-mutant, CEBPA AML are estimated to have germline inheritance of 1 CEBPA mutation, with a nearly 100% penetrant risk of AML based on current evidence. 21, 24, 25 The 10% predicted frequency of germline CEBPA mutation inheritance is important, in that a 10% chance of germline inheritance is often an accepted standard to trigger referral for genetic testing in solid tumors. 26 DDX41 mutations in myeloid malignancies are also often dual-mutated at diagnosis, although the frequency of germline inheritance in the setting of biallelic mutations is not well elucidated to date, and the risk of malignancy in DDX41 carriers also is currently undetermined. 27, 28 Recent studies of families with familial platelet disorder related to germline RUNX1 mutations (ie, familial platelet disorder/predisposition to myeloid malignancies [FPD/MM]) or ANKRD26 mutation reported bone marrow abnormalities in otherwise asymptomatic individuals, highlighting the importance of morphologic clues and the pathologists' role in the identification of such cases. 29, 30 The inclusion of myeloid neoplasms with germline predisposition in the 2016 World Health Organization classification of myeloid and acute leukemias further supports and stresses the role of interdisciplinary collaborations. 7 Thus, it becomes apparent that clinical and laboratory evaluation can augment the concern or consideration for genetic evaluation; however, these features cannot reliably identify all patients for whom genetic testing is indicated. Variable expression and incomplete penetrance of these disorders add to interpretative challenges; furthermore, it remains unknown how often germline mutations leading to inherited hematologic malignancies are spontaneous de novo events, in which the family history would be uninformative. It is interesting to note that, given the inadequacy of clinical and family history to appropriately identify all patients who may benefit from germline genetic testing, agnostic testing approaches, regardless of patient and family history, have recently been reported for some tumor types. Particularly among pediatric, breast, ovarian, and colorectal cancer populations, pathogenic germline mutations have been identified in approximately 8% to 11% regardless of family history, suggesting that genetic testing approaches may have utility in some unselected populations. [31] [32] [33] [34] At our institution, we currently use an algorithm similar to and adapted from several recent expert opinion panels on optimal screening and diagnostic evaluation to identify appropriate patients for referral to our Hereditary Hematologic Malignancies Clinic (HHMC) (Fig. 1) . Specifically, we recommend referral for hematology-focused genetic counseling in patients who have a family history of hematologic malignancies or any personal history of clinical or laboratory features known to be associated with hematologic malignancy syndromes. 35 In addition, we recommend referral for inherited bone marrow failure syndrome evaluation in any patient diagnosed with MDS at age 40 years or younger or patients with hypocellular MDS, AML, and/or bone marrow failure at any age, for whom the workup includes both a clastogenic assay for FA (ie, diepoxybutane or mitomycin C) and telomere flow-fluorescence in situ hybridization for telomere biology disorders.
GENE PANEL ASSAYS TO IMPROVE GERMLINE DETECTION
Because multiple mutations with varied prognostic and therapeutic implications are often present at initial diagnosis in patients who have hematologic malignancies, it is increasingly common to use NGS-based platforms for the evaluation of mutation status as more practical and costeffective methods than numerous single-gene assays. In addition, as a result of the recent US Food and Drug Administration approval of targeted therapies like midostaurin for fms-related tyrosine kinase 3 (FLT3)-mutated AML and enasidenib for isocitrate dehydrogenase 2 (IDH2)-mutated AML, 36, 37 comprehensive and multigene mutation detection is now required to adequately inform treatment decisions, making gene panel assays a standard and more cost-effective approach. 38 Panel-based testing is especially critical in establishing a comprehensive tumor genotype in the setting of a limited sample, which generally precludes genotyping using single-gene assays. Although the specific genes analyzed on hematologic malignancy gene panels vary by platform and institution, most panels share a core set of approximately 25 genes that are frequently mutated in acute leukemias and myeloid neoplasms. 39 These core genes include several (ie, CEBPA, GATA2, RUNX1, tumor protein 53 [TP53], and others) that can be mutated in the germline of the patient. This offers both an opportunity and a challenge to determine variants of potential germline origin and of clinical significance identified within panels designed principally for somatic mutation analysis.
The lack of a normal control for NGS testing in patients with active hematologic malignancy prevents the ability to definitively distinguish whether a mutation is of germline or somatic origin; blood samples contain the circulating hematologic malignancy, and saliva samples in leukemic patients typically are contaminated with peripheral blood. 40 In the absence of a matched germline control, variant allele frequency (VAF) estimation and publically available data sets provide important clues to the possible germline origin of a variant. For instance, mutations in genes of possible germline inheritance that are present at heterozygous (HET) (range, 40%-60%) or homozygous (HOMO) (approximately 80%) allelic frequency (the latter because of somatic loss of heterozygosity) should inspire additional evaluation. For initial identification of a previously unannotated possible germline variant, we consider a VAF >40% for further evaluation. This is based on our historic observations on known germline variants and the VAF distribution patterns for less common germline variants, which primarily fall in the VAF range from 40% to 60% (HET) or >80% (HOMO), but also less commonly have a VAF range from 61% to 79%. Figure 2 illustrates the observed VAF distribution of various germline variants in our cohort and highlights the value of maintaining a local VAF database for statistical and visual identification of variants. The ability of NGS panels to detect variants in multiple genes allows comparison of a VAF in a suspected germline variant with known, well established somatic variants in the same sample. The concurrent presence of known , and the y-axis depicts total observations for specific VAFs in our patient cohort. G>A indicates guanosine-to-adenosine substitution; rs, reference single-nucleotide polymorphism number; T>C, thymidine-to-cytosine substitution. somatic mutation(s) at subheterozygous VAF (<40%) with a suspected germline variant at HET/HOMO VAF may provide a useful clue in support of germline origin. In general, the greater the difference in VAF, the stronger the suspicion is for germline origin. A VAF <30% for a known somatic mutation generally translates into a difference >10% for a HET variant. In cases of multiple, known somatic mutations with unique VAFs, the highest value (presumed dominant clone) is used to account for multiple clonal populations. When VAFs for all variants in the sample are in the HET/HOMO range, follow-up testing, either at the time of clinical remission or in the presence of an unchanged HET/HOMO VAF at multiple treatment time points, may further support germline origin. Correlation with available clinical history, tumor burden, and copy number alteration is critical for further determination on a case-by-case basis. Approaches to help ensure the accuracy of VAF determination include: 1) ensuring adequate sequencing coverage, 2) using molecular barcodebased removal of polymerase chain reaction duplicates, and 3) correcting for copy number alterations involving the genes of interest. The gene function and nature of the mutation also should be taken into account for further evaluation; for example, mutations in tumor-suppressor genes often are associated with high VAF, even in the somatic setting, because of associated loss of the wild-type copy.
It is noteworthy that the VAF range on gene panel testing that may represent true heterozygosity is not standardized and often is considered as a VAF >35% or >40%; and, currently, each laboratory must establish local, validated thresholds. 41 In addition, publically available databases, such as the Exon Sequencing Project (ESP), the Single Nucleotide Polymorphism database (dbSNP), the 1000 Genomes Project (1000Genome), the Exome Aggregation Consortium (ExAC) database, the Human Gene Mutation Database (HGMD), ClinVar, the Catalogue of Somatic Mutations in Cancer (COSMIC), and The Cancer Genome Atlas (TCGA), should be integrated into the review of all variants to determine whether a variant has been reported previously in the germline setting and whether the clinical significance of that variant is known. Rare or novel variants, as expected may have limited information available in such databases for further determination.
Once a potential variant of germline origin has been identified, the next challenge is to determine clinical significance and the need for confirmatory germline testing on cultured skin fibroblasts. In this aspect, NGS panels for hematologic malignancies differ from solid tumor testing, in which concurrent, paired tumor-normal testing performed up-front allows definitive determination of germline versus somatic status of all detected variants. In contrast, the need for initial genetic counseling based on results from hematologic panels-is first and foremost to evaluate the requirement for germline confirmation. Some of the genes involved in hereditary hematologic malignancies can have multiple polymorphisms, making it a challenge to distinguish variants that require further evaluation from variants that are clearly nonpathogenic. To allow systematic evaluation, documentation, and clinical decision-making when suspected germline variants are detected, our institution has established criteria and a workflow for the multidisciplinary review of suspected germline variants to determine which variants require additional evaluation (Fig. 3) . Publically available tools for determining clinical significance (ie, ESP, dbSNP, 1000Genome, ExAC, HGMD, ClinVar, COSMIC, and TCGA) similar to those used for determining germline origin, as described above, should be interrogated. Prediction of the impact of a variant on protein function using in silico prediction tools (ie, SIFT [sorting intolerant from tolerant], PolyPhen2 [polymorphism phenotyping], MutTaster [Mutation Taster], CADD [computer-aided architectural design]) may be a useful adjunct but is not recommended for clinical reporting, and such tools are to be used for reference purposes only. 42 Functional studies to determine the pathogenicity of variants of uncertain significance should be performed if possible, although this approach is limited and often unavailable.
Although an NGS-based prognostic panel cannot identify germline events without a germline control sample, germline inheritance may be more likely in certain settings, and gene panel assay results must consider this possibility, as supported by the current joint consensus recommendation of the Association for Molecular Pathology, the American Society of Clinical Oncology, and the College of American Pathologists. 42 On the basis of the available evidence, guidelines recommend reporting clinically significant pathogenic germline variants detected on somatic panels as tier I (strong clinical significance) or tier II (potential clinical significance), which warrant genetic counseling and evaluation of nontumor tissue for confirmation of germline origin. As the available evidence regarding germline variants continues to evolve, we report all germline variants noted in <20% of our patient cohort to allow future determination of clinical significance, irrespective of evidence in the current literature. Overall, NGS panels can provide a useful screening tool to systematically improve the detection of variants of potential germline origin for additional evaluation.
It is important to note that NGS-based gene panels may not have been designed to identify large gene deletions, duplications, or structural variants and may require additional testing that is optimized for such mutations. In addition, many pathologic germline variants occur outside of the transcribed exons, such as intronic variants in GATA2 or 5 0 -promoter mutations in ANKRD26; thus, gene panels that fail to appropriately analyze these regions may provide false-negative results. 19, 43 Ultimately and undeniably, mutation panels intended for prognostication purposes are not definitive for germline analysis, and referral for dedicated genetic counseling and genetic testing is essential if an inherited predisposition to cancer is suspected.
IDENTIFICATION OF AN INHERITED LEUKEMIA PREDISPOSITION THROUGH NGS PANEL RESULTS
The section below provides informative examples of patients at our institution whose NGS panel results triggered a referral to cancer genetics, in which an inherited predisposition to hematologic malignancy was identified. A woman aged 60 years was referred to our institution with newly diagnosed AML after a routine complete blood count (CBC) before a planned knee replacement demonstrated pancytopenia, and a subsequent bone marrow evaluation identified 35% myeloid blasts. Conventional cytogenetic analysis demonstrated 46,XX,11,der(1;14)(3)/46,XX. 17 Molecular characterization using an 81-gene MDS/AML NGS platform revealed 2 mutations in DDX41: c.571-1G>A and c.1574G>A (p.R525H), a frequent, recurrent hot-spot somatic mutation in individuals with germline DDX41 mutations. 27 The intronic splice-site mutation was present at approximately 50% VAF. Because this suggested a possible germline mutation, the patient was referred for genetic counseling and testing. She reported a family history of postmenopausal breast cancer and unspecified solid tumors in second-degree relatives; however, she denied a family history of hematologic malignancies. The patient underwent comprehensive genetic counseling and elected to proceed with germline evaluation for DDX41 by undergoing skin fibroblast analysis. Germline genetic testing revealed the c.572-1G>A mutation, a pathogenic mutation associated with predisposition to myeloid neoplasms. The p.R525H mutation was not detected in the germline, consistent with its role as an acquired and secondary mutation. The patient achieved a morphologic remission after standard induction/ consolidation chemotherapy and was referred for allogeneic stem cell transplantation (SCT) evaluation. Her only sibling was not a human leukocyte antigen-identical match, so her 2 children were considered as haploidentical donors. Because of the patient's germline DDX41 status, both of the patient's adult children were referred for genetic counseling and predictive DDX41 genetic testing before proceeding with haploidentical SCT to identify the most appropriate donor. Donor-derived leukemia has been reported in several DDX41-affected families, occurring after allogeneic SCT from a mutation-positive, related donor. Notably, these cases of donor-derived leukemia reportedly occurred without any hematopoietic abnormalities identified in the mutationpositive donors, indicating that HSC stress during SCT and/ or host factors can promote malignant expansion. 44, 45 In our case, the patient's children were evaluated expeditiously for comprehensive genetic counseling and testing, and both children elected to proceed with single-site germline analysis of c.572-1G>A on peripheral blood. Fortunately, both children tested negative for the familial DDX41 mutation, rendering them appropriate potential haploidentical-SCT donors and confirming that their lifetime risk for myeloid neoplasms is not increased over that in the general population. In addition, they were then provided information about their own children, who have no chance to inherit the DDX41 alteration based on known autosomal-dominant inheritance. A girl aged 13 years presented with longstanding thrombocytopenia since infancy, requiring platelet transfusions between birth and 12 months of age. She did not require additional transfusions and, after early childhood, no longer obtained routine blood work, although she continued to experience frequent epistaxis and gum bleeding. At the time of a routine sports physical, a CBC revealed a platelet count of 46 3 10 3 /lL, and the patient was referred to a hematologist, who evaluated her for possible immune thrombocytopenic purpura versus MDS. A bone marrow aspiration revealed 60% cellularity without blast elevation; trilineage hematopoiesis with mild unilineage dysplasia, including increased megakaryocytes with atypical morphology; and no evidence of MDS or other malignancy. Conventional cytogenetic analysis revealed 46,XX,inv(9)(p12q13), a known chromosomal polymorphism in the general population. Molecular analysis reported 2 alterations: RUNX1 c.1098_1103dupCGG-CAT and tet methylcytosine dioxygenase 2 (TET2) c.1598T>C. A germline origin for both variants was favored based on the VAF and lack of underlying hematologic malignancy, and she was referred for genetic counseling and evaluation. The patient is an only child; her mother was healthy and reported a normal platelet count on a recent CBC. The patient's maternal grandmother was diagnosed with multiple myeloma. A maternal great uncle died of an unspecified blood disorder. The patient has no contact with her biologic father; his personal and family medical histories are entirely unknown. Germline testing confirmed the pathogenic RUNX1 mutation c.1098_1103dupCGGCAT in the patient, consistent with FPD/MM. The patient continues under active surveillance with stable, mild thrombocytopenia and does not require transfusions. Genetic counseling has provided the opportunity for additional family members to undergo evaluation, in addition to the opportunity of an unhurried discussion of inheritance regarding future children as well as accessibility of assisted reproductive technologies, such as preimplantation genetic diagnosis, if desired.
THE ROLE OF GENETIC COUNSELING
Genetic counseling is a critical component of the optimal care and management of patients who have a possible inherited cancer syndrome to help them better understand and adapt to the medical, psychological, and familial implications of genetic disorders. Individuals with predispositions to hematologic malignancies face unique concerns and challenges with regard to their personal well being as well as the implications for family members. The necessity of prompt counseling and testing of family members who are potential SCT donors cannot be overstated; however, the ethical considerations surrounding the rapid genetic evaluation of a potentially inherited cancer predisposition syndrome-often without any current clinically available preventative approaches-must be carefully discussed with the acknowledgment, promotion, and respect of individual autonomy and informed consent. Future studies must focus on how family members and patients with hematologic malignancies understand and are affected by germline and somatic genetic testing. Additional avenues of counseling, such as telemedicine approaches for patients in areas without established genetic counselors who have expertise in hereditary hematologic malignancies, also must be assessed.
CONCLUSIONS
Inherited predispositions to hematologic malignancy are significantly more common than previously considered. With improved community and physician awareness, more patients who may benefit from genetic testing are referred for counseling and evaluation. In addition to careful attention to the personal and family history of the patient, a thorough evaluation of morphologic findings and cautious evaluation of standard-of-care, panel-based molecular testing performed for prognostication and informed treatment decisions also may be used to identify patients who warrant referral for genetic testing. 
